UNSPSC 51385202: Proquazone

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C18H18N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 42VPJ2980S, chemically known as 2(1h)-quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- but generally known as proquazone, which bears US NIH Compound Identifier 31508. European Medicines Agency schedules Proquazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10127MIG.

UNSPSC 51385202 Proquazone is a Commodity code that in practice encompasses naloxone, drug deactivation systems, generic pharmaceuticals, and over-the-counter products procured by state and local health agencies, multistate cooperative purchasing alliances, and county health departments to support community health and pharmacy benefit programs. State and local buyers under this code range from county health departments managing emergency response inventories to state health and human services commissions operating statewide pharmacy benefit programs and multistate cooperative purchasing consortiums serving multiple jurisdictions. The work solicited includes the purchase and distribution of pharmaceutical products through authorized wholesalers, direct-to-manufacturer prescription fulfillment arrangements, and emergency medical countermeasures such as naloxone kits for overdose response; vendors typically must meet FDA compliance, cGMP certification, Drug Supply Chain Security Act (DSCSA) requirements, and maintain contractual relationships with authorized pharmaceutical wholesalers.

Recent activity centers in Florida and Minnesota, with preliminary market-intelligence work underway in Texas. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building, with responses due July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities, with proposals due March 26, 2026 and resulting agreements effective July 1, 2026; vendors must supply through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC, with pricing weighted at 75 percent of evaluation. The Texas Health and Human Services Commission posted an RFI in April 2026 to gather market intelligence on implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program outside traditional pharmacy benefit manager and group purchasing organization channels.